stocks logo

ITRM

Iterum Therapeutics PLC
$
0.825
-0.005(-0.602%)1D
  • Overview
  • Forecast
  • Valuation
  • Earnings
Line
Line
|
Candle
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
0.8701
Open
0.8315
VWAP
0.84
Vol
456.79K
Mkt Cap
33.00M
Low
0.8211
Amount
384.15K
EV/EBITDA(TTM)
--
Total Shares
16.55M
EV
52.57M
EV/OCF(TTM)
--
P/S(TTM)
--
Iterum Therapeutics plc is a clinical-stage pharmaceutical company. The Company develops differentiated anti-infectives. It offers ORLYNVAH (sulopenem in an oral tablet formulation) medicine, which is an oral penem antibiotic for the treatment of uncomplicated urinary tract infections caused by the designated microorganisms Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis in adult women. Sulopenem is a potent, thiopenem antibiotic delivered intravenously which is active against bacteria that belong to the group of organisms known as gram-negatives and cause urinary tract and intra-abdominal infections. The Company operates as a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.
Show More
2 Analyst Rating
up Image
748.48% Upside
Wall Street analysts forecast ITRM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ITRM is 7.00 USD with a low forecast of 5.00 USD and a high forecast of 9.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
up Image
748.48% Upside
Current: 0.825
sliders
Low
5.00
Averages
7.00
High
9.00
H.C. Wainwright
H.C. Wainwright
initiated
$9
2025-05-08
Reason
H.C. Wainwright assumed coverage of Iterum Therapeutics with a Buy rating and $9 price target. Iterum is a pre-commercial stage company with an FDA approved product, the analyst tells investors in a research note. The firm says the company has the potential to deliver in urinary tract infections and infectious disease.
HC Wainwright & Co.
Ed Arce
Strong Buy
Reiterates
$5
2024-09-10
Reason
HC Wainwright & Co.
Ed Arce
Strong Buy
Maintains
$6 → $5
2024-08-15
Reason

Valuation Metrics

The current forward P/E ratio for Iterum Therapeutics PLC (ITRM.O) is -2.84, compared to its 5-year average forward P/E of -2.01. For a more detailed relative valuation and DCF analysis to assess Iterum Therapeutics PLC 's fair value, click here.

Forward PE

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-2.01
Current PE
-2.84
Overvalued PE
0.42
Undervalued PE
-4.44

Forward EV/EBITDA

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-0.91
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
1.16
Undervalued EV/EBITDA
-2.98

Forward PS

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
393.08
Current PS
4.25
Overvalued PS
2102.38
Undervalued PS
-1316.23

Financials

Annual
Quarterly
FY2025Q1
N/A
Total Revenue
FY2025Q1
YoY :
-39.80%
-3.71M
Operating Profit
FY2025Q1
YoY :
-31.12%
-4.89M
Net Income after Tax
FY2025Q1
YoY :
-69.57%
-0.14
EPS - Diluted
FY2025Q1
YoY :
-76.60%
-3.06M
Free Cash Flow
FY2025Q1
N/A
Gross Profit Margin - %
FY2025Q1
N/A
FCF Margin - %
FY2025Q1
N/A
Net Margin - %

Trading Trends

Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months

ITRM News & Events

Events Timeline

2025-06-30 (ET)
2025-06-30
07:03:07
Iterum Therapeutics appoints Coyne as CCO
select
2025-06-25 (ET)
2025-06-25
07:10:36
Iterum Therapeutics announces publication of REASSURE trial in NEJM Evidence
select
2025-06-11 (ET)
2025-06-11
07:12:26
Iterum Therapeutics announces partnership for commercialization services
select
Sign Up For More Events

News

5.0
06-30Newsfilter
Iterum Names Christine Coyne as Chief Commercial Officer to Lead ORLYNVAH™ Launch and Commercial Growth
9.0
06-25Newsfilter
Iterum Therapeutics Announces Publication of REASSURE Trial in NEJM Evidence
7.5
06-11Newsfilter
Iterum Therapeutics Announces Partnership for Commercialization Services
Sign Up For More News

FAQ

arrow icon

What is Iterum Therapeutics PLC (ITRM) stock price today?

The current price of ITRM is 0.825 USD — it has decreased -0.6 % in the last trading day.

arrow icon

What is Iterum Therapeutics PLC (ITRM)'s business?

arrow icon

What is the price predicton of ITRM Stock?

arrow icon

What is Iterum Therapeutics PLC (ITRM)'s revenue for the last quarter?

arrow icon

What is Iterum Therapeutics PLC (ITRM)'s earnings per share (EPS) for the last quarter?

arrow icon

What changes have occurred in the market's expectations for Iterum Therapeutics PLC (ITRM)'s fundamentals?

arrow icon

How many employees does Iterum Therapeutics PLC (ITRM). have?

arrow icon

What is Iterum Therapeutics PLC (ITRM) market cap?